ConforMIS Surges 9% Following Clinical Study Updates

Shares of ConforMIS Inc CFMS, a medical technology company, were trading higher by 9 percent by mid-Wednesday afternoon after the company announced positive results from several clinical studies.

ConforMIS stated the results from the studies will be fully presented at the 2016 British Association for Surgery of the Knee (BASK) Annual Meeting which takes places Wednesday through Thursday.

One such study compared the knee motion of patients with an implanted ConforMIS iTotal knee replacement versus an off-the shelf "Legacy" or "Modern" total knee replacement. The study showed that ConforMIS' patients "exhibited assessed motion patterns more closely resembling a normal knee" versus patients with Legacy and Modern implants.

"Replicating the normal motion pattern of a patient's knee is an important aspect of achieving a more stable, natural feeling knee and restoring normal function," said William Kurtz, MD, Chief of Orthopedics at Baptist Hospital in Nashville, TN and clinical investigator in the study. "This study supports my clinical observations; ConforMIS patients achieve natural knee movement and stability unlike patients with legacy and modern generation off-the-shelf implants. I am very encouraged by my patients' recovery with ConforMIS implants, namely better outcomes, faster recovery and higher return to normal everyday activities."